Summary of findings table ‐ Moxibustion plus usual care vs sham moxibustion plus usual care
Adverse events · breech presentation
1 finding from 1 review
- no estimate extracted1 study · 272 participantsGRADE not reported
Findings
What do systematic reviews say?
2,434 questions · 2,594 findings · 269 reviews
No studies found 543 · 20.9%GRADE not reported 191 · 7.4%Very low 676 · 26.1%Low 732 · 28.2%Moderate 399 · 15.4%High 53 · 2%
Summary of findings table ‐ Moxibustion plus usual care vs usual care
Need for ECV · breech presentation
Summary of findings table ‐ Moxibustion plus usual care showed no clear difference in need for ECV compared with usual care (low certainty).
1 finding from 1 review
- RR 0.62 [0.32, 1.21]4 studies · 692 participantsLow
Summary of findings table ‐ Moxibustion plus usual care vs usual care
Caesarean section · breech presentation
Summary of findings table ‐ Moxibustion plus usual care showed no clear difference in caesarean section compared with usual care (moderate certainty).
1 finding from 1 review
- RR 0.94 [0.83, 1.05]6 studies · 1030 participantsModerate
Summary of findings table ‐ Moxibustion plus usual care vs usual care
Premature rupture of membranes · breech presentation
Summary of findings table ‐ Moxibustion plus usual care showed no clear difference in premature rupture of membranes compared with usual care (low certainty).
1 finding from 1 review
- RR 1.31 [0.17, 10.21]3 studies · 402 participantsLow
Summary of findings table ‐ Moxibustion plus usual care vs usual care
Use of oxytocin · breech presentation
Summary of findings table ‐ Moxibustion plus usual care probably leads to lower use of oxytocin compared with usual care (moderate certainty).
1 finding from 1 review
- RR 0.28 [0.13, 0.6]1 study · 161 participantsModerate
Summary of findings table ‐ Moxibustion plus usual care vs usual care
Low arterial cord blood pH (< 7.10) · breech presentation
Summary of findings table ‐ Moxibustion plus usual care showed no clear difference in cord blood pH less than 7.1 compared with usual care (low certainty).
1 finding from 1 review
- RR 3 [0.32, 28.38]1 study · 212 participantsLow
Summary of findings table ‐ Moxibustion plus usual care vs usual care
Adverse events · breech presentation
It is very uncertain whether summary of findings table ‐ Moxibustion plus usual care changes adverse events compared with usual care (very low certainty).
1 finding from 1 review
- RR 48.33 [3.01, 774.86]1 study · 122 participantsVery low
Summary of findings table ‐ Moxibustion plus usual care vs sham moxibustion plus usual care
Non‐cephalic presentation at birth · breech presentation
Summary of findings table ‐ Moxibustion plus usual care probably leads to lower non‐cephalic presentation at birth compared with sham moxibustion plus usual care (moderate certainty).
1 finding from 1 review
- RR 0.74 [0.58, 0.95]1 study · 272 participantsModerate
Summary of findings table ‐ Moxibustion plus usual care vs sham moxibustion plus usual care
Need for ECV ‐ not reported · breech presentation
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Usual care vs immunosuppressive withdrawal after monotherapy
Clinical relapse · Participants with Crohn's disease in remission
Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 0.42 [0.24, 0.72]4 studies · 215 participantsLow
Usual care vs immunosuppressive withdrawal after monotherapy
New CD‐related complications · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 0.34 [0.06, 2.08]2 studies · 135 participantsVery low
Usual care vs immunosuppressive withdrawal after monotherapy
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 0.88 [0.67, 1.17]3 studies · 186 participantsLow
Usual care vs immunosuppressive withdrawal after monotherapy
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 3.29 [0.35, 30.8]2 studies · 134 participantsVery low
Usual care vs immunosuppressive withdrawal after monotherapy
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 2.59 [0.35, 19.04]2 studies · 135 participantsVery low
Usual care vs immunosuppressive withdrawal after combination therapy
Relapse · Participants with Crohn's disease in remission
Usual care showed no clear difference in relapse at 12 or 24 months compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 1.02 [0.68, 1.52]2 studies · 111 participantsLow
Usual care vs immunosuppressive withdrawal after combination therapy
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 1.11 [0.44, 2.81]2 studies · 111 participantsLow
Usual care vs immunosuppressive withdrawal after combination therapy
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 1 [0.21, 4.66]1 study · 80 participantsVery low
Alpha‐blocker as adjuvant medical expulsive therapy plus usual care vs usual care
Stone clearance assessed by imaging · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
- Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults 2020 · Cochrane Headline outcomes onlyno estimate extracted36 studies · 4084 participantsLow
Alpha‐blocker as adjuvant medical expulsive therapy plus usual care vs usual care
Auxiliary treatment · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
- Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults 2020 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 1251 participantsLow
Alpha‐blocker as adjuvant medical expulsive therapy plus usual care vs usual care
Major adverse events · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
- Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults 2020 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 747 participantsLow